Lupus & antiphospholipid syndrome
An immunometabolic signature of major depressive disorder in systemic lupus erythematosus
Authors' conclusion
SLEMDD is associated with an immunometabolic signature involving alterations in Treg phenotype, gut microbiota composition, and metabolic pathways.
Study context
- Population
- Patients with systemic lupus erythematosus (SLE) from the LUPIL-2 study; validation in an independent cohort from the TRANSIMMUNOM studyLUPIL-2 study
- Participants
- 99 patients
- Exposure
- SLEMDD vs SLEnon-MDD
- Outcome
- Candidate immunometabolic biomarkers associated with SLEMDD (flow cytometry immune phenotyping, gut microbiota profiling, targeted mass spectrometry-based metabolomics)
Methodological detailsunsupervised principal component analysis, supervised decision tree classification, independent validation cohort (TRANSIMMUNOM)
- Unsupervised principal component analysis
- Supervised decision tree classification
- Independent validation cohort (TRANSIMMUNOM)
Main finding
As reported in the abstract
Immunometabolic signature of SLEMDD
Immune profile: decreased naïve CD4⁺ T cells and naïve Tregs, increased ICOS⁺ effector memory Tregs; classification accuracy
94%
Integrative signature (Treg activation, microbial metabolites, immune pathways) distinguishing SLEMDD from SLEnon-MDD; accuracy up to
85%
Observational data: associations, not effects.
Original publication
An immunometabolic signature of major depressive disorder in systemic lupus erythematosus. Ann Rheum Dis. Published 20 March 2026. doi:10.
Composed by AI from the published abstract and checked against it. How Briefs are made →